Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

Griebel G, Stemmelin J, Gal CS, Soubrié P.

Curr Pharm Des. 2005;11(12):1549-59. Review.

PMID:
15892661
2.

The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.

Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.

J Neuroendocrinol. 2004 Apr;16(4):356-61. Review.

PMID:
15089974
3.

The vasopressin V1b receptor as a therapeutic target in stress-related disorders.

Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R.

Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):191-200. Review.

PMID:
12769799
4.

Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

Jiménez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M, Rivera F, Maffrand JP, Rodés J.

J Pharmacol Exp Ther. 2000 Oct;295(1):83-90.

PMID:
10991964
5.

Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway.

Mallat A, Fouassier L, Préaux AM, Gal CS, Raufaste D, Rosenbaum J, Dhumeaux D, Jouneaux C, Mavier P, Lotersztajn S.

J Clin Invest. 1995 Jul;96(1):42-9.

Supplemental Content

Support Center